Wells Fargo upgrades Cleveland-Cliffs to $14 on hidden 2027 upside

Wells Fargo upgraded Cleveland-Cliffs to Overweight from Equal Weight and raised its price target to $14 from $12; shares rose 4.8% pre-market. The bank projects $2.65 billion of 2027 EBITDA and roughly $560 million in free cash flow, with net leverage falling to 2.6x from 15.2x in Q2, citing Stelco pricing gains and contract repricing. The tactical thesis carries risks from a potential rollback of the 50% Section 232 steel tariff, economic slowdown and the Mesabi Metallics lawsuit, which has a potential $5.7 billion total liability.

Analysis

The key question is not whether steel prices stay at peak levels, but whether Cleveland-Cliffs can convert lagged pricing into cash before the cycle turns. Contract resets and Stelco pricing could create a temporary earnings catch-up; if realized, cash generation would reduce balance-sheet risk and narrow some of the discount to Nucor and Steel Dynamics. But the estimate is unusually sensitive to assumptions about contract premiums, CRU discounts and tariff protection. These are analyst scenarios, not yet demonstrated cash earnings.

Tariffs are a double-edged catalyst: they support domestic pricing, but a rollback could compress the price umbrella across U.S. producers while CLF’s fixed-cost base and leverage amplify downside. A slowdown would have a similar asymmetric effect. The Mesabi Metallics litigation is a separate, potentially material tail risk; improvement in operating leverage does not resolve it. New sheet capacity is a later-cycle risk, but could weigh on forward pricing before it appears in current results.

Near term, the upgrade-driven gap may get ahead of evidence. Over 1–3 months, watch realized net pricing, contract repricing disclosures, free cash flow and debt reduction; over 6–18 months, the thesis depends on those gains persisting through normalization. The headline does not match the article body, so verify the source before acting. The contrarian opportunity is a conditional CLF relative-value position, not an unconditional bet on the steel cycle.

Key Decisions for Investors

• Do not chase the initial gap. Consider a small, beta-aware long CLF versus a short basket of NUE and STLD only after price action stabilizes and upcoming results confirm improved realized pricing or cash conversion. This expresses the lagged-repricing thesis while reducing broad steel-price exposure; it is not a clean hedge against CLF-specific leverage or litigation risk.
• Keep the position tactical and size below a conventional steel-cycle exposure. Reassess if realized pricing fails to track the contract-reset thesis, cash generation does not reduce debt, or U.S. HRC weakens materially below the roughly $1,000/st normalization assumption used in the analyst case.
• Treat a Section 232 rollback, material deterioration in demand, or an adverse Mesabi Metallics litigation development as thesis-invalidating catalysts. Verify the lawsuit status and potential financial exposure rather than relying on the probability-weighted discount in the analyst valuation.
• Before adding, seek company-level evidence on repriced contract volumes, achieved premiums and CRU-linked discounts; absent that disclosure, the 2027 EBITDA upside remains an estimate rather than an investable near-term catalyst.